Table 1 Demographics and pathologic characteristics of the study subjects.
From: Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer
| Â | N = 96 |
|---|---|
Age (mean ± SD) | 65.2 ± 9.1 |
Sex (M:F) | 1:1.04 |
Operation | Â |
  Whipple's operation | 20 (20.8%) |
  PPPD | 39 (40.6%) |
  Distal | 30 (31.3%) |
  Total | 6 (6.3%) |
Adjuvant chemotherapy | 87 (90.6%) |
  Gemcitabine | 56 (58.3%) |
  5-FU | 21 (21.9%) |
  Unknown | 10 (10.4%) |
Recurrence | 58 (60.4%) |
  Local | 23 (24.0%) |
  Distant | 50 (52.1%) |
Follow up (median, months) | 14.3 (range, 2.9-45.9) |
R status | Â |
  R0 | 76 (79.2%) |
  R1 | 14 (14.6%) |
  R2 | 6 (6.3%) |
AJCC 7th staging | Â |
  Stage IA | 3 (3.1%) |
  Stage IB | 0 |
  Stage IIA | 41 (42.7%) |
  Stage IIB | 50 (52.1%) |
  Stage III | 1 (1.0%) |
  Stage IV | 1 (1.0%) |
Histologic differentiation | Â |
  Well differentiated | 3 (3.1%) |
  Moderately differentiated | 84 (87.5%) |
  Poorly differentiated | 9 (9.4%) |
Perineural invasion | 83 (86.5%) |
Endolymphatic invasion | 39 (40.6%) |
Endovenous invasion | 25 (26.0%) |